Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 2/20 | 0.73 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.69 |
| ▸ | FLT3 | P36888 | 10/20 | 0.68 |
| ▸ | KDR | P35968 | 8/20 | 0.68 |
| ▸ | FLT4 | P35916 | 4/20 | 0.68 |
| ▸ | KIT | P10721 | 2/20 | 0.68 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.66 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.66 |
| ▸ | AURKA | O14965 | 1/20 | 0.66 |
| ▸ | MET | P08581 | 1/20 | 0.66 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.66 |
| ▸ | RET | P07949 | 2/20 | 0.62 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.59 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.56 |
| ▸ | CDK2 | P24941 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2111085 | 0.91 | KDR (0.77) | ALKLRRK2FLT3KDRFLT4 | |
| SCHEMBL4489518 | 0.88 | ALK (0.71) | ALKLRRK2FLT3KDRFLT4 | |
| SCHEMBL4489516 | 0.88 | ALK (0.71) | ALKLRRK2FLT3KDRFLT4 | |
| SCHEMBL3273838 | 0.86 | ALK (0.79) | ALKLRRK2FLT3KDRFLT4 | |
| SCHEMBL16486529 | 0.85 | ALK (0.78) | ALKFLT3KDRFLT4KIT | |
| SCHEMBL16490745 | 0.85 | ALK (0.78) | ALKFLT3KDRFLT4KIT | |
| SCHEMBL18631714 | 0.84 | ALK (0.76) | ALKLRRK2FLT3KDRFLT4 | |
| SCHEMBL2112712 | 0.84 | ALK (0.76) | ALKLRRK2FLT3KDRFLT4 | |
| SCHEMBL31726830 | 0.84 | ALK (0.76) | ALKLRRK2FLT3KDRFLT4 | |
| SCHEMBL3723130 | 0.84 | ALK (0.76) | ALKFLT3KDRFLT4KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029580-B1 | NOVEL INDOL-PYRROL DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DISEASES | SCHEBO BIOTECH AG (DE) | 2010-06-16 | — | — | EP | claimed |
| EP-2029580-B1 | NOVEL INDOL-PYRROL DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DISEASES | SCHEBO BIOTECH AG (DE) | 2010-06-16 | — | — | EP | disclosed |
| US-20100035251-A1 | BioMarkers for the Progression of Alzheimer's Disease | HE YUNSHENG | 2010-02-11 | — | — | US | disclosed |
| EP-2035582-A2 | BIOMARKERS FOR THE PROGRESSION OF ALZHEIMER'S DISEASE | Novartis AG (CH) | 2009-03-18 | — | — | EP | disclosed |
| WO-2009030270-A1 | DIHYDROINDOLE DERIVATIVES USEFUL IN PARKINSON'S DISEASE | NOVARTIS AG (CH) | 2009-03-12 | — | — | WO | disclosed |
| WO-2007149798-A2 | BIOMARKERS FOR THE PROGRESSION OF ALZHEIMER'S DISEASE | NOVARTIS AG (CH) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035251-A1 | BioMarkers for the Progression of Alzheimer's Disease | LRRK2, PSEN2, CLK2 | ALK 4140/4885LRRK2 1/4885FLT3 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.